News broke Monday that Teva Pharmaceutical Industries will acquire Auspex Pharmaceuticals. Existing investors will be wondering if they are getting enough in this buyout.
Chris Lange Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.
24/7 Wall St. has put together a preview of some of the larger companies reporting quarterly results in the coming week.
Teva Pharmaceutical announced on Monday that the FDA approved the first generic equivalent to Nexium delayed-release capsules in the United States.
A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.
Friday's top analyst upgrades, downgrades and initiations include Citrix Systems, GoPro, Hewlett-Packard, Microsoft, Oracle and Teva Pharmaceutical.
Cowen asked the analysts which stocks should be on their shopping lists. Here are the six with the biggest upside potential.
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Wednesday, July 23, 2014. They include DuPont, General Electric, King, Microsoft, Xilinx and McDonald's.
In a recent research report, UBS specifically mentions six companies that it advises investors not to use an option strategy on, as they expect near-term catalysts to drive the stocks higher.
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Friday, June 27, 2014. They include Alcoa, Cigna, Intel, Molina Healthcare, Teva Pharmaceutical and UnitedHealth.
Teva Pharmaceutical is finding a bit of a sell-the-news reaction to its first-quarter earnings report. The company said revenues rose 2% from a year ago and net income rose by 8%.
Jon C. Ogg The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
These are the top analyst upgrades, downgrades and initiations for Tuesday, April 22, 2014. They include AMD, ARM Holdings, Barrick Gold, Netflix, Teva Pharmaceutical and Valero Energy.
Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent on its top-selling multiple-sclerosis drug.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on March 19, 2014. They include Compugen, Enterprise Products Partners, Juniper Networks, Suncor Energy and Yingli Green…
